查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1613332

皮膚科治療市場：按治療層級、給藥途徑、適應症、最終用戶、分銷管道 - 全球預測 2025-2030

Dermatology Drugs Market by Therapeutic Class (Antifungals, Corticosteroids, Immunosuppressants), Route of Administration (Oral, Parenteral Injection, Topical), Indication Type, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年皮膚科治療市場規模為314億美元，預計2024年將達342.3億美元，複合年成長率為9.83%，2030年將達605.6億美元。

皮膚病治療的範圍包括廣泛的治療產品，旨在治療痤瘡、乾癬、濕疹和皮膚感染疾病等皮膚相關問題。皮膚科治療在緩解症狀、改善皮膚健康和增強患者信心方面發揮重要作用。最終用途主要包括醫院、皮膚科診所、藥房和私人消費者。市場的推動因素包括人們對皮膚病的認知不斷提高、藥物配方的進步以及對微創治療的需求不斷成長。隨著遠距皮膚病學和個人化醫療方法的興起，以及越來越多的患有皮膚病的老年人口，預計會出現新的商機。與生物技術公司的策略聯盟以及透過數位平台推廣可以提供利潤豐厚的成長機會。

主要市場統計
基準年[2023] 314億美元
預測年份 [2024] 342.3億美元
預測年份 [2030] 605.6億美元
複合年成長率（%） 9.83%

然而，市場面臨一些挑戰，包括嚴格的監管流程、高昂的研發成本以及與皮膚病治療相關的潛在副作用。此外，新興市場的可及性差以及學名藥的競爭也是市場擴張的主要障礙。生物製藥、藥物傳輸系統中的奈米技術以及有機和天然皮膚病產品的開發等領域提供了有前景的成長途徑。探索人工智慧主導的解決方案來預測皮膚狀況和最佳化藥物功效也可能徹底改變該領域。皮膚科藥品市場的本質是高度動態的，其特點是技術快速進步和消費者對更安全、更有效的治療方法的偏好不斷變化。希望在這一領域獲得優勢的公司必須專注於全面的研究和開發，並與醫療保健提供者和監管機構建立牢固的合作夥伴關係。對不斷變化的患者需求和監管環境保持敏感非常重要。此外，透過資料分析獲得深入的市場洞察對於主動應對潛在的市場變化並靈活響應新趨勢和消費者期望是必要的。總體而言，以患者為中心的方法與創新相結合對於克服挑戰並最大限度地發揮皮膚病治療市場的成長潛力至關重要。

市場動態：揭示快速發展的皮膚科治療市場的關鍵市場洞察

供需的動態交互作用正在改變皮膚科治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 乾癬、濕疹、痤瘡和皮膚癌等皮膚病的盛行率增加
    • 藥物開發方面的技術進步和強大的皮膚科治療產品線
    • 擴大採用生物製藥來抗治療性疾病
  • 市場限制因素
    • 嚴格而漫長的監管核准流程
  • 市場機會
    • 加大個人化醫療投入，遠端醫療應用不斷增多
    • 皮膚科產品向天然和有機成分的重大轉變
  • 市場挑戰
    • 處理成本高、監管政策嚴格

波特五力：駕馭皮膚科藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解皮膚科藥物市場的外部影響

外部宏觀環境因素在塑造皮膚科治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解皮膚科治療藥物市場的競爭狀況

皮膚病治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣皮膚病治療市場供應商的績效評估

FPNV定位矩陣是評估皮膚科治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃皮膚科治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，皮膚病治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 乾癬、濕疹、痤瘡和皮膚癌等皮膚病的增加
      • 藥物開發的技術進步和強大的皮膚科藥物產品線
      • 擴大採用生物製藥來抗治療性疾病
    • 抑制因素
      • 嚴格而漫長的監管核准流程
    • 機會
      • 對個人化醫療的新投資和遠端醫療應用的增加
      • 皮膚科產品向天然和有機成分的重大轉變
    • 任務
      • 處理成本高、監管政策嚴格
  • 市場區隔分析
    • 治療層級：免疫抑制劑在皮膚科的普及，用於治療嚴重或難治性皮膚病
    • 最終使用者：由於社會對外表和健康的日益重視，對美容和皮膚科診所的興趣日益增加。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療層級的皮膚科藥物市場

  • 抗真菌藥物
  • 皮質類固醇
  • 免疫抑制劑
  • 類視色素A

第7章 皮膚科治療藥物市場：依給藥途徑分類

  • 口服
  • 腸外注射
  • 話題

第 8 章：按適應症類型分類的皮膚科治療藥物市場

  • 粉刺
  • 異位性皮膚炎
  • 乾癬
  • 皮膚癌

第9章皮膚科治療藥物市場：依最終使用者分類

  • 美容/皮膚科診所
  • 診斷中心及實驗室
  • 醫院

第10章皮膚科治療藥物市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房

第11章 北美和南美皮膚科藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區皮膚科治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲皮膚科治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Almirall 與微軟宣布合作開發皮膚病新治療方法
    • FDA核准Arcutis 的 ZORYVE（羅氟司特）外用泡沫 0.3% 用於治療脂漏性皮膚炎
    • 禮來公司進軍皮膚科領域，推出乾癬治療藥物
  • 戰略分析和建議

公司名單

  • Allergan plc by Abbvie Inc.
  • Almirall SA
  • Amgen Inc.
  • Arcutis Biotherapeutics, Inc.
  • Asterisk Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited
  • DermBiont, Inc.
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Galderma SA
  • GlaxoSmithkline plc
  • Johnson & Johnson Services, Inc.
  • Leo Pharma A/S
  • Lupin Ltd
  • Mayne Pharma Group Ltd
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Roivant Sciences Ltd.
  • Shinom Cosmeceuticals
Product Code: MRR-950610B5BBD5

The Dermatology Drugs Market was valued at USD 31.40 billion in 2023, expected to reach USD 34.23 billion in 2024, and is projected to grow at a CAGR of 9.83%, to USD 60.56 billion by 2030.

The scope of dermatology drugs encompasses a wide range of therapeutic products designed to treat skin-related issues, including acne, psoriasis, eczema, and skin infections. Dermatology drugs play a crucial role in alleviating symptoms, improving skin health, and boosting patient confidence. The end-use scope primarily includes hospitals, dermatology clinics, pharmacies, and individual consumers. The market is driven by increasing awareness of skin conditions, advances in pharmaceutical formulations, and a growing demand for minimally invasive treatments. Emerging opportunities are anticipated due to the rise in teledermatology and personalized medicine approaches, as well as the expanding geriatric population experiencing skin ailments. Strategic partnerships with biotech firms and leveraging digital platforms for outreach can present lucrative growth opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 31.40 billion
Estimated Year [2024] USD 34.23 billion
Forecast Year [2030] USD 60.56 billion
CAGR (%) 9.83%

However, the market confronts several challenges, such as stringent regulatory processes, high R&D costs, and the potential side effects associated with dermatology drugs. Limited accessibility in developing regions and heavy competition from generic drugs also pose significant barriers to market expansion. Innovation is key to overcoming these obstacles; areas like biopharmaceuticals, nanotechnology in drug delivery systems, and the development of organic and natural-based dermatology products offer promising avenues for growth. The exploration of AI-driven solutions for predicting skin conditions or optimizing drug efficacy could also revolutionize the sector. The nature of the dermatology drug market is highly dynamic, characterized by rapid technological advancements and a consumer preference shift towards safer, more effective treatments. Companies looking to assert dominance in this sphere must emphasize comprehensive research and development, alongside fostering strong alliances with healthcare providers and regulatory bodies. Remaining attuned to the evolving patient needs and regulatory landscapes will be critical. Additionally, gaining detailed market insights through data analytics will be necessary to preemptively address potential market shifts, ensuring agile adaptations to emerging trends and consumer expectations. Overall, a patient-centric approach, coupled with innovation, will be paramount in navigating the challenges and maximizing the growth potential within the dermatology drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dermatology Drugs Market

The Dermatology Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of skin diseases such as psoriasis, eczema, acne, and skin cancer
    • Technological advancements in drug development, along with a strong pipeline of dermatological drugs
    • Increasing adoption of biologics for treatment-resistant conditions among geriatric condition
  • Market Restraints
    • Stringent and time-consuming regulatory approval process
  • Market Opportunities
    • Emerging investment in personalized medicine, and rising application in telemedicine
    • Notable shift towards natural and organic ingredients in dermatological products
  • Market Challenges
    • High treatment costs and stringent regulatory policy

Porter's Five Forces: A Strategic Tool for Navigating the Dermatology Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dermatology Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dermatology Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dermatology Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dermatology Drugs Market

A detailed market share analysis in the Dermatology Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dermatology Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dermatology Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dermatology Drugs Market

A strategic analysis of the Dermatology Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dermatology Drugs Market, highlighting leading vendors and their innovative profiles. These include Allergan plc by Abbvie Inc., Almirall S.A., Amgen Inc., Arcutis Biotherapeutics, Inc., Asterisk Laboratories, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cipla Limited, Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited, DermBiont, Inc., Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche AG, Galderma S.A., GlaxoSmithkline plc, Johnson & Johnson Services, Inc., Leo Pharma A/S, Lupin Ltd, Mayne Pharma Group Ltd, Merck & Co., Inc, Novartis AG, Pfizer Inc., Roivant Sciences Ltd., and Shinom Cosmeceuticals.

Market Segmentation & Coverage

This research report categorizes the Dermatology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across Antifungals, Corticosteroids, Immunosuppressants, and Retinoids.
  • Based on Route of Administration, market is studied across Oral, Parenteral Injection, and Topical.
  • Based on Indication Type, market is studied across Acne, Atopic dermatitis, Psoriasis, and Skin cancer.
  • Based on End-User, market is studied across Aesthetic & Dermatology Clinics, Diagnostic Centers & Laboratories, and Hospitals.
  • Based on Distribution Channel, market is studied across Hospital pharmacies and Retail pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of skin diseases such as psoriasis, eczema, acne, and skin cancer
      • 5.1.1.2. Technological advancements in drug development, along with a strong pipeline of dermatological drugs
      • 5.1.1.3. Increasing adoption of biologics for treatment-resistant conditions among geriatric condition
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent and time-consuming regulatory approval process
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging investment in personalized medicine, and rising application in telemedicine
      • 5.1.3.2. Notable shift towards natural and organic ingredients in dermatological products
    • 5.1.4. Challenges
      • 5.1.4.1. High treatment costs and stringent regulatory policy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapeutic Class: Proliferation of immunosuppressants in dermatology for the treatment of severe or refractory skin conditions
    • 5.2.2. End-User: High inclination towards aesthetic and dermatology clinics owing to increasing societal emphasis on appearance and wellness
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dermatology Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Antifungals
  • 6.3. Corticosteroids
  • 6.4. Immunosuppressants
  • 6.5. Retinoids

7. Dermatology Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parenteral Injection
  • 7.4. Topical

8. Dermatology Drugs Market, by Indication Type

  • 8.1. Introduction
  • 8.2. Acne
  • 8.3. Atopic dermatitis
  • 8.4. Psoriasis
  • 8.5. Skin cancer

9. Dermatology Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Aesthetic & Dermatology Clinics
  • 9.3. Diagnostic Centers & Laboratories
  • 9.4. Hospitals

10. Dermatology Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital pharmacies
  • 10.3. Retail pharmacies

11. Americas Dermatology Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Dermatology Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Dermatology Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Almirall and Microsoft announce partnership for the development of novel treatments for skin diseases
    • 14.3.2. FDA Approves Arcutis' ZORYVE (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis
    • 14.3.3. Eli Lilly forays into dermatological space with launch of psoriasis drug
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Allergan plc by Abbvie Inc.
  • 2. Almirall S.A.
  • 3. Amgen Inc.
  • 4. Arcutis Biotherapeutics, Inc.
  • 5. Asterisk Laboratories
  • 6. AstraZeneca plc
  • 7. Bayer AG
  • 8. Bristol-Myers Squibb Company
  • 9. Cipla Limited
  • 10. Concert Pharmaceuticals by Sun Pharmaceutical Industries Limited
  • 11. DermBiont, Inc.
  • 12. Dr. Reddy's Laboratories
  • 13. Eli Lilly and Company
  • 14. F. Hoffmann-La Roche AG
  • 15. Galderma S.A.
  • 16. GlaxoSmithkline plc
  • 17. Johnson & Johnson Services, Inc.
  • 18. Leo Pharma A/S
  • 19. Lupin Ltd
  • 20. Mayne Pharma Group Ltd
  • 21. Merck & Co., Inc
  • 22. Novartis AG
  • 23. Pfizer Inc.
  • 24. Roivant Sciences Ltd.
  • 25. Shinom Cosmeceuticals

LIST OF FIGURES

  • FIGURE 1. DERMATOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DERMATOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. DERMATOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. DERMATOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DERMATOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DERMATOLOGY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETINOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PARENTERAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ACNE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY AESTHETIC & DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DERMATOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES DERMATOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM DERMATOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. DERMATOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. DERMATOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023